Accelerating Medicines Partnership Program - Schizophrenia (AMP-SCZ)
The AMP-SCZ research network is recruiting a large cohort of approximately 2,000 clinically high-risk young people and 640 control participants. Participants are aged 12-30 years and are recruited from 42 participating investigative sites based in 14 countries across North America, South America, Australia, Asia and Europe, including Spain, Italy, the United Kingdom, the United States of America, Singapore and China. The clinical participants complete screening, baseline assessments and a series of follow-up assessments over a period of 24 months, while the control participants complete screening and baseline assessments and a subset (5 per site) complete month 2, 12 and 24 visits.
Study design
Cohort - clinical, Cohort - research programme
Number of participants at first data collection
1,042 (participants)
Recruitment is ongoing
Age at first data collection
Varied (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2023
Primary Institutions
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
National Institute of Mental Health (NIMH)
University of Melbourne
Profile paper DOI
Funders
American Psychiatric Association Foundation (APA Foundation)
Boehringer Ingelheim
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Foundation for the National Institutes of Health (FNIH)
Ongoing?
Yes
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – unspecified
- Voice capture (e.g. timbre, emotional fluctuations)
- Wearable devices
- None
- Electroencephalography (EEG)
- Magnetic Resonance Imaging (MRI)
- Geographic, spatial & environmental data
- Social media & technology use data
Engagement
Keywords
